William Blair Small-Mid Cap Growth Fund on Twist Bioscience Corp.
Thesis
Twist Bioscience's competitive moat comes from miniaturizing DNA manufacturing on silicon, enabling far greater scale than legacy methods. The company is delivering broad momentum across DNA Synthesis and Protein Solutions and Next Generation Sequencing, while AI-enabled drug discovery remains an important demand tailwind. Pharmaceutical customers continue to use the platform for speed, quality and cost advantages as margins move toward profitability targets. The fund trimmed the position but still expects the secular shift toward synthetic biology to support sustainable market-share gains.
“Twist’s value proposition of high-throughput, high quality and low-cost pricing is differentiated and should allow for sustainable share gains”